PUBLIC CONTRACT · 2023
Adalimumab BIOSSIMILAR 40 mg/0.8 ml Sol inj Caneta 0.8 ml SC (AMGEVITA)
- Contract value
- €4,834.70
- Signed on
- 10 October 2023
- Procedure
- Ao abrigo de acordo-quadro (art.º 258.º)
This page lays out the fields published on Portal BASE and says when a field is unavailable. It is not an assessment of the contract's merit, legality or impact.
Record 11684713PUBLISHED SUBJECT
Adalimumab BIOSSIMILAR 40 mg/0.8 ml Sol inj Caneta 0.8 ml SC (AMGEVITA)
Parties involved
- Place of performance
- Portugal, Viana do Castelo, Viana do Castelo
- NUTS region
- PT111 - Alto Minho
WHO BID
Awardee and competitors
Companies that IMPIC lists as the awardee and as competitors in this procedure.
- Awardee
- AMGEN BIOFARMACEUTICA, LDA · Tax ID 502942959
Values and timeline
- Contract price
- €4,834.70
- Procedure base price
- €4,834.70
- Total effective price
- Not reported on Portal BASE
- Publication date
- 8 September 2025
- Award date
- 10 October 2023
- Signing date
- 10 October 2023
- Performance period
- 30 days
The contract price is the value agreed in the contract, not the amount paid.
Procedure and framework
- Contract type
- Aquisição de bens móveis
- Procedure type
- Ao abrigo de acordo-quadro (art.º 258.º)
- Award criterion
- Monofator
- CPV code
- 33000000-0 - Equipamento médico, medicamentos e produtos para cuidados pessoais
- Legal basis
- Artigo 258.º do Código dos Contratos Públicos
- Regime
- Código dos Contratos Públicos (DL111-B/2017) e Lei n.º 30/2021, de 21.05
- Framework agreement
- CP 2022/55 - Acordo quadro para fornecimento de medicamentos diversos
- Centralised procedure
- No
- Environmental criterion
- No
- Notice
- Not stated
- Procedure identifier
- 7820376
Compare with other contracts
Search the same body, supplier, place or type of service to understand the context of the published index.